Dr Falk Pharma UK

What Dr Falk Pharma UK does

Dr Falk Pharma UK Ltd is a UK pharmaceutical subsidiary of the German family-owned Dr Falk Pharma group, established in 2005 and operating from Bourne End with a 9-employee footprint. Its commercial activity centres on the distribution and detailing of four branded prescription medicines in the gastroenterology and hepatology therapeutic areas: Budenofalk (budesonide) and Salofalk (mesalazine) for inflammatory bowel disease (ulcerative colitis, Crohn's disease, microscopic colitis); Jorveza for eosinophilic oesophagitis (EoE); and Ursofalk (ursodeoxycholic acid) for liver diseases including Primary Biliary Cholangitis.

The business model is sales-led and prescription-driven: products are dispensed through UK pharmacies and prescribing channels (NHS and independent), with the company targeting gastroenterology and hepatology specialists. Commercial reach is reinforced by the FalkPlus HCP community platform (education, events, resources) and the related Falk Foundation e.V. charitable programme, including Falk Forums, Falk Futures, Symposia, and joint awards with Guts UK, BASL, and the Falk Foundation Awards Ireland. There is no indication of OTC, consumer, or digital-therapeutic revenue lines.

Technically, the offering is built on small-molecule drug formulations, regulatory-approved indications, and a content/event community layer (FalkPlus) rather than on a proprietary software platform or novel data assets. Pricing is not publicly disclosed and is administered through normal UK NHS and pharmacy channels. The UK entity is operationally tied to a parent group with country presence across roughly 14 European markets plus Australia and Russia, but the UK entity itself shows no recent funding, M&A, leadership change, or product launch signals in the supplied data.

Name

Dr Falk Pharma UK

Legal name

Dr. Falk Pharma UK Ltd

Website

https://drfalk.co.uk

Company type

Private

Founded year

1960

Operating status

Operating

Headcount range

1–10 employees

Short description

Dr Falk Pharma UK Ltd is the UK distribution subsidiary of Dr Falk Pharma, distributing four branded prescription medicines for inflammatory bowel disease, eosinophilic oesophagitis, and chronic liver disease to UK gastroenterologists, hepatologists, and their patients via NHS and pharmacy channels.

Ownership category

akta.pro rank

Product category

Gastroenterology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

akta.pro secondary industry

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

Keywords

• Prescription pharmaceuticals
• Gastroenterology treatments
• Hepatology medicines
• Inflammatory bowel disease
• Digestive health drugs

Headquarters

HQ city

UK

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Marketing or Sales, Personnel, Operations

Revenue model

1. Pharmaceutical Product Sales: Dr. Falk Pharma UK generates revenue through the sale of prescription pharmaceutical products, specifically Budenofalk, Jorveza, Salofalk, and Ursofalk, which are used in the treatment of inflammatory bowel disease, liver diseases, and eosinophilic oesophagitis.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Dr. Falk Pharma UK develops and distributes prescription pharmaceutical medicines for digestive and metabolic diseases. The portfolio comprises four branded products (Budenofalk, Jorveza, Salofalk, Ursofalk) targeting inflammatory bowel disease, eosinophilic oesophagitis, and autoimmune liver diseases, complemented by the FalkPlus digital platform providing healthcare professional education, events, and clinical resources.

Product overview

Dr Falk Pharma UK operates as a research-based pharmaceutical company specializing in digestive and metabolic medicine. The company offers a portfolio of four branded medications: Budenofalk® and Salofalk® for inflammatory bowel disease (ulcerative colitis and Crohn's disease), Jorveza® for eosinophilic oesophagitis, and Ursofalk® for liver diseases (including Primary Biliary Cholangitis). These products are complemented by the FalkPlus platform, which provides healthcare professionals with access to expert education, events, and clinical resources for managing digestive and metabolic diseases. The company focuses on gastroenterology and hepatology therapeutic areas.

Differentiator

Problem solved

Functional benefit

Brands

• Falk+ / FalkPlus: Healthcare professional community platform providing access to expert education, events, and resources for the management of digestive and metabolic diseases.

Products and services

• Budenofalk A budesonide-based prescription medicine for treating inflammatory bowel conditions, including Crohn's disease and other inflammatory disorders of the gastrointestinal tract, prescribed by gastroenterology specialists in the UK.
• Jorveza A prescription medicine for eosinophilic oesophagitis (EoE), a chronic progressive inflammatory disease affecting the oesophageal lining, prescribed by gastroenterologists and specialists in the UK.
• Salofalk A mesalazine-based prescription medicine for inflammatory bowel disease, including ulcerative colitis and Crohn's disease, prescribed by gastroenterology specialists in the UK.
• Ursofalk A ursodeoxycholic acid-based prescription medicine for liver diseases, including Primary Biliary Cholangitis (PBC) and other cholestatic conditions, prescribed by hepatology specialists in the UK.
• FalkPlus A digital healthcare professional platform providing access to expert education, live educational events, product information, patient support tools, and clinical resources for managing digestive and metabolic diseases, targeted at UK gastroenterology and hepatology specialists.

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Falk FoundationcoreStrategic or Co-development PartnerThe Falk Foundation e.V. is a separate charitable organisation that provides a platform for experts in gastroenterology and hepatology to meet and communicate with one another. It offers continuing education opportunities for physicians and pharmacists. The Falk Foundation and Dr. Falk Pharma share the Falk name and operate in a coordinated manner, with the Foundation providing educational events (Falk Forums, Falk Futures, Symposia) and awards programmes (Falk Foundation/Guts UK Awards, Falk Foundation/BASL Awards) that complement Dr. Falk Pharma's commercial activities.
• Guts UKminorGTM or Marketing PartnerDr. Falk Pharma partners with Guts UK through the Falk Foundation/Guts UK Awards programme, supporting recognition of excellence in gastroenterology and digestive health.
• British Association for the Study of the Liver (BASL)minorGTM or Marketing PartnerDr. Falk Pharma partners with BASL through the Falk Foundation/BASL Awards, supporting recognition in hepatology and liver disease research.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Market position

Strengths4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/DrFalkUK
• LinkedInlinkedin.com/company/dr-falk-pharma-uk

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dr Falk Pharma UK